Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Bakkavor boosts full-year profits outlook

(Sharecast News) - Convenience food maker Bakkavor Group boosted its full-year profits forecast on Wednesday, following a strong first half. Like-for-like revenues from continuing operations at the FTSE 250 firm improved 1.2% to £1.1bn in the 26 weeks to 28 June, while reported revenues rose 0.9% to £1.1bn. Adjusted operating profits jumped 9.8% to £61.5m

As a result, the business - which has agreed to be taken over by pre-packed sandwich specialist Greencore in a £1.2bn deal - now expects full-year adjusted operating profits from continuing operations to be towards the upper end of guidance, for between £120m and £126m.

Mike Edwards, chief executive, said: "The business is in great shape, with momentum expected to continue in the second half.

"Looking further ahead, we have accelerated the delivery of our medium-term margin target of 6% to the 2026 full-year, one year ahead of plan."

Bakkavor sold its China business in July, and its Hong Kong operations in March, and both have therefore been excluded from the interim results.

Greencore and Bakkavor agreed to join forces earlier this year. The Competition and Markets Authority confirmed this week that it was opening a formal acquisition into the deal, which is set to create a convenience food giant with combined revenues of around £4bn.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.